Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics

References

• Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, and Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–29. doi:10.1038/nbt.2287.
   PubMed Web of Science ®Google Scholar
• Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4(1):53. doi:10.1186/s40425-016-0158-5.
   PubMedGoogle Scholar
• Pol JG, Levesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, et al., Trial Watch: oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology. 2018;7(12):e1503032. doi:10.1080/2162402X.2018.1503032.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–62. doi:10.1038/nrd4663.
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Lichty BD, Bell JC. Oncolytic viruses: therapeutics with an identity crisis. EBioMedicine. 2016;9:31–36. doi:10.1016/j.ebiom.2016.06.046.
   PubMed Web of Science ®Google Scholar
• Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs. 2019;33(5):485–501. doi:10.1007/s40259-019-00367-0.
   PubMed Web of Science ®Google Scholar
• Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18(9):689–706. doi:10.1038/s41573-019-0029-0.
   PubMed Web of Science ®Google Scholar
• Fisher K, Hazini A, Seymour LW. Tackling HLA deficiencies head on with oncolytic viruses. Cancers (Basel). 2021;13(4). doi:10.3390/cancers13040719.
   Web of Science ®Google Scholar
• Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Monoclonal antibodies: technologies for early discovery and engineering. Crit Rev Biotechnol. 2018;38(3):394–408. doi:10.1080/07388551.2017.1357002.
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Greiff V, Karatt-Vellatt A, Muyldermans S, Jenkins TP. Animal immunization, in vitro display technologies, and machine learning for antibody discovery. Trends Biotechnol. 2021. doi:10.1016/j.tibtech.2021.03.003.
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, and Bell JC Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6(7):821–25. doi:10.1038/77558.
   PubMed Web of Science ®Google Scholar
• Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008;6:529–40.
   PubMed Web of Science ®Google Scholar
• Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev. 2009;61(7–8):554–71. doi:10.1016/j.addr.2009.03.013.
   PubMed Web of Science ®Google Scholar
• Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol. 2014;12(1):23–34. doi:10.1038/nrmicro3140.
   PubMed Web of Science ®Google Scholar
• Ruiz AJ, Russell SJ. MicroRNAs and oncolytic viruses. Curr Opin Virol. 2015;13:40–48. doi:10.1016/j.coviro.2015.03.007.
   PubMed Web of Science ®Google Scholar
• Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, and Nettelbeck DM. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther. 2004;11(23):1694–702. doi:10.1038/sj.gt.3302346.
   PubMed Web of Science ®Google Scholar
• Kaufmann JK, Nettelbeck DM. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med. 2012;18(7):365–76. doi:10.1016/j.molmed.2012.04.008.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Barber GN. Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. Cancer Cell. 2018;33(4):599–605. doi:10.1016/j.ccell.2018.03.011.
   PubMed Web of Science ®Google Scholar
• Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, et al. Therapeutic monoclonal antibodies targeting immune checkpoints for the treatment of solid tumors. Antibodies (Basel). 2019;8(4):1-54.
   PubMedGoogle Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–68.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al., Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e10. doi:10.1016/j.cell.2017.08.027.
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, Sharma A, Garbe C, Singh P, and Mehnert JM. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer. 2019;121(5):417–20. doi:10.1038/s41416-019-0530-6.
   PubMed Web of Science ®Google Scholar
• Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors. Mol Ther Oncolytics. 2019;13:14–21. doi:10.1016/j.omto.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT, and Nettelbeck DM. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology. 2004;320(1):121–34. doi:10.1016/j.virol.2003.11.028.
   PubMed Web of Science ®Google Scholar
• Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9(1):86–120. doi:10.1007/s13238-017-0457-8.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021;13(1):1860476. doi:10.1080/19420862.2020.1860476.
   PubMed Web of Science ®Google Scholar
• Shah A, Rauth S, Aithal A, Kaur S, Ganguly K, Orzechowski C, Varshney GC, Jain M, and Batra SK. The current landscape of antibody-based therapies in solid malignancies. Theranostics. 2021;11(3):1493–512. doi:10.7150/thno.52614.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Sharkey RM. Using antibodies to target cancer therapeutics. Expert Opin Biol Ther. 2012;12(9):1173–90. doi:10.1517/14712598.2012.693472.
   PubMed Web of Science ®Google Scholar
• Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111(6):538–49. doi:10.1093/jnci/djz035.
   PubMedGoogle Scholar
• Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Robak T, le Coutre PD, Gjertsen BT, Troussard X, Roboz GJ, Karlin L, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021;14(1):35. doi:10.1186/s13045-020-01004-y.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys. 2012;526(2):194–205. doi:10.1016/j.abb.2012.03.001.
   PubMed Web of Science ®Google Scholar
• de Bruyn M, Bremer E, Helfrich W. Antibody-based fusion proteins to target death receptors in cancer. Cancer Lett. 2013;332(2):175–83. doi:10.1016/j.canlet.2010.11.006.
   PubMed Web of Science ®Google Scholar
• Jordaan S, Akinrinmade OA, Nachreiner T, Cremer C, Naran K, Chetty S, and Barth S. Updates in the development of immunornases for the selective killing of tumor cells. Biomedicines. 2018;6(1). doi:10.3390/biomedicines6010028.
   Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. The Oncologist. 2015;20(6):660–73. doi:10.1634/theoncologist.2014-0465.
   PubMed Web of Science ®Google Scholar
• Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745–70.
   PubMed Web of Science ®Google Scholar
• Lee A, Sun S, Sandler A, Hoang T. Recent progress in therapeutic antibodies for cancer immunotherapy. Curr Opin Chem Biol. 2018;44:56–65. doi:10.1016/j.cbpa.2018.05.006.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167.
   PubMed Web of Science ®Google Scholar
• Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(10):568–86. doi:10.1038/s41568-019-0183-z.
   PubMed Web of Science ®Google Scholar
• Dalziel M, Beers SA, Cragg MS, Crispin M. Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics. Glycobiology. 2018;28:697–712.
   PubMed Web of Science ®Google Scholar
• Beckman RA, von Roemeling R, Scott AM. Monoclonal antibody dose determination and biodistribution into solid tumors. Ther Deliv. 2011;2(3):333–44. doi:10.4155/tde.10.91.
   PubMedGoogle Scholar
• Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402–08.
   PubMed Web of Science ®Google Scholar
• Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med. 1998;42:225–41.
   PubMedGoogle Scholar
• Nessler I, Khera E, Vance S, Kopp A, Qiu Q, Keating TA, Abu-Yousif AO, Sandal T, Legg J, Thompson L, et al., Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res. 2020;80(6):1268–78. doi:10.1158/0008-5472.CAN-19-2295.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153–63. doi:10.1021/bc100261d.
   PubMed Web of Science ®Google Scholar
• Kraft TE, Richter WF, Emrich T, Knaupp A, Schuster M, Wolfert A, and Kettenberger H. Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis. MAbs. 2020;12(1):1683432. doi:10.1080/19420862.2019.1683432.
   PubMed Web of Science ®Google Scholar
• Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, and Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61(12):4750–55.
   PubMed Web of Science ®Google Scholar
• Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, and Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71(6):2250–59. doi:10.1158/0008-5472.CAN-10-2277.
   PubMed Web of Science ®Google Scholar
• Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, and Weinstein JN. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A. 1995;92(19):8999–9003. doi:10.1073/pnas.92.19.8999.
   PubMed Web of Science ®Google Scholar
• Tang Y, Cao Y. Modeling the dynamics of antibody-target binding in living tumors. Sci Rep. 2020;10(1):16764. doi:10.1038/s41598-020-73711-y.
   PubMed Web of Science ®Google Scholar
• Staflin K, Zuch de Zafra CL, Schutt LK, Clark V, Zhong F, Hristopoulos M, Clark R, Li J, Mathieu M, Chen X, et al., Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. JCI Insight. 2020;5(7):1-15.
   Web of Science ®Google Scholar
• Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, Van Hall T. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers (Basel). 2021;13(2). doi:10.3390/cancers13020287.
   PubMed Web of Science ®Google Scholar
• Lin WW, Lu YC, Chuang CH, Cheng TL. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci. 2020;27(1):76. doi:10.1186/s12929-020-00652-z.
   PubMed Web of Science ®Google Scholar
• De Lombaerde E, De Wever O, De Geest BG. Delivery routes matter: safety and efficacy of intratumoral immunotherapy. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188526. doi:10.1016/j.bbcan.2021.188526.
   PubMed Web of Science ®Google Scholar
• Chen JD, Yang Q, Yang AG, Marasco WA, Chen SY. Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum Gene Ther. 1996;7(13):1515–25. doi:10.1089/hum.1996.7.13-1515.
   PubMed Web of Science ®Google Scholar
• Paul S, Bizouarne N, Dott K, Ruet L, Dufour P, Acres RB, and Kieny MP. Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther. 2000;7(4):615–23. doi:10.1038/sj.cgt.7700161.
   PubMed Web of Science ®Google Scholar
• Paul S, Snary D, Hoebeke J, Allen D, Balloul JM, Bizouarne N, Dott K, Geist M, Hilgers J, Kieny MP, et al. Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. Hum Gene Ther. 2000;11(10):1417–28. doi:10.1089/10430340050057495.
   PubMed Web of Science ®Google Scholar
• Noël D, Pelegrin M, Kramer S, Jacquet C, Skander N, Piechaczyk M. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther. 2002;13(12):1483–93. doi:10.1089/10430340260185111.
   PubMed Web of Science ®Google Scholar
• Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol. 2002;76(17):8769–75. doi:10.1128/JVI.76.17.8769-8775.2002.
   PubMed Web of Science ®Google Scholar
• Schnepp BC, Johnson PR. Vector-mediated in vivo antibody expression. Microbiol Spectr. 2014;2(4):Aid-0016-2014. doi:10.1128/microbiolspec.AID-0016-2014.
   PubMedGoogle Scholar
• Yang L, Wang P. Passive immunization against HIV/AIDS by antibody gene transfer. Viruses. 2014;6(2):428–47. doi:10.3390/v6020428.
   PubMed Web of Science ®Google Scholar
• Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, and Jooss K. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol. 2005;23(5):584–90. doi:10.1038/nbt1087.
   PubMed Web of Science ®Google Scholar
• Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, Su C, Yang Q, Li Y, Sham J, et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res. 2006;12(20):6179–85. doi:10.1158/1078-0432.CCR-06-0746.
   PubMed Web of Science ®Google Scholar
• Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, and Worgall S. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology. 2008;378(1):79–85. doi:10.1016/j.virol.2008.04.016.
   PubMed Web of Science ®Google Scholar
• Schlake T, Thess A, Thran M, Jordan I. mRNA as novel technology for passive immunotherapy. Cell Mol Life Sci. 2019;76:301–28.
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011;481(7379):81–84. doi:10.1038/nature10660.
   PubMed Web of Science ®Google Scholar
• Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther. 2000;1(4):376–82. doi:10.1006/mthe.2000.0050.
   PubMed Web of Science ®Google Scholar
• Paul S, Regulier E, Rooke R, Stoeckel F, Geist M, Homann H, Balloul JM, Villeval D, Poitevin Y, Kieny MP, et al. Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther. 2002;9(5):470–77. doi:10.1038/sj.cgt.7700461.
   PubMed Web of Science ®Google Scholar
• Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, and Suzuki M. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res. 2017;77(8):2040–51. doi:10.1158/0008-5472.CAN-16-1577.
   PubMed Web of Science ®Google Scholar
• Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, and Suzuki M. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. Mol Ther. 2017;25(11):2440–51. doi:10.1016/j.ymthe.2017.09.010.
   PubMed Web of Science ®Google Scholar
• Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK, et al. Oncolytic adenovirus armed with bite, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther. 2020;28(5):1251–62. doi:10.1016/j.ymthe.2020.02.016.
   PubMed Web of Science ®Google Scholar
• Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrelli LL, Vinci M, Ferrari F, Salviato E, et al. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021;9(5). doi:10.1136/jitc-2020-001930.
   Web of Science ®Google Scholar
• Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017;9(8):1067–87. doi:10.15252/emmm.201707567.
   PubMed Web of Science ®Google Scholar
• Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, Campo L, Bryant RJ, Verrill C, Lambert A, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 2018;78(24):6852–65. doi:10.1158/0008-5472.CAN-18-1750.
   PubMed Web of Science ®Google Scholar
• Scott EM, Jacobus EJ, Lyons B, Frost S, Freedman JD, Dyer A, Khalique H, Taverner WK, Carr A, Champion BR, et al. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. J Immunother Cancer. 2019;7(1):320. doi:10.1186/s40425-019-0807-6.
   PubMed Web of Science ®Google Scholar
• Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, Cattaneo RB, and Fielding AK. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther. 2003;7(1):62–72. doi:10.1016/S1525-0016(02)00033-3.
   PubMed Web of Science ®Google Scholar
• Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, and Gatta V. Retargeting strategies for oncolytic herpes simplex viruses. Viruses. 2016;8(3):63. doi:10.3390/v8030063.
   PubMed Web of Science ®Google Scholar
• Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ, et al. CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma. Oncotarget. 2018;9(16):12971–81. doi:10.18632/oncotarget.24191.
   PubMedGoogle Scholar
• Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. 2001;61:6377–81.
   PubMed Web of Science ®Google Scholar
• van Beusechem VW, Mastenbroek DC, van den Doel PB, Lamfers ML, Grill J, Würdinger T, Haisma HJ, Pinedo HM, and Gerritsen WR. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther. 2003;10(23):1982–91. doi:10.1038/sj.gt.3302103.
   PubMed Web of Science ®Google Scholar
• Gil M, Bieniasz M, Wierzbicki A, Bambach BJ, Rokita H, Kozbor D. Targeting a mimotope vaccine to activating Fc gamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J Immunol. 2009;183(10):6808–18. doi:10.4049/jimmunol.0900364.
   PubMed Web of Science ®Google Scholar
• Seth P, Wang ZG, Pister A, Zafar MB, Kim S, Guise T, and Wakefield L. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther. 2006;17(11):1152–60. doi:10.1089/hum.2006.17.1152.
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhang Z, Guise T, Seth P. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther. 2010;21(11):1623–29. doi:10.1089/hum.2010.018.
   PubMed Web of Science ®Google Scholar
• Hu Z, Gerseny H, Zhang Z, Chen YJ, Berg A, Zhang Z, Stock S, and Seth P. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther. 2011;19(9):1609–18. doi:10.1038/mt.2011.114.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu W, Peng D, Wang H, Zhang X, Wang H, Xiao F, Zhu Y, Ji Y, Gulukota K, et al. An oncolytic adenovirus targeting transforming growth factor β inhibits protumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy. Hum Gene Ther. 2019;30(9):1117–32. doi:10.1089/hum.2019.059.
   PubMed Web of Science ®Google Scholar
• Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, and Chen SY. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020;11(1):1395. doi:10.1038/s41467-020-15229-5.
   PubMed Web of Science ®Google Scholar
• Loya SM, Zhang X. Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator. Gene Ther. 2015;22(3):237–46. doi:10.1038/gt.2014.113.
   PubMed Web of Science ®Google Scholar
• Passaro C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin Cancer Res. 2019;25(1):290–99. doi:10.1158/1078-0432.CCR-18-2311.
   PubMed Web of Science ®Google Scholar
• Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, et al.Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, and Coffin RS. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019;7(1):214. doi:10.1186/s40425-019-0682-1.
   PubMed Web of Science ®Google Scholar
• Lin C, Ren W, Luo Y, Li S, Chang Y, Li L, Xiong D, Huang X, Xu Z, Yu Z, et al. Intratumoral delivery of a PD-1-blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade. Cancer Immunol Res. 2020;8(5):632–47. doi:10.1158/2326-6066.CIR-19-0628.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hu X, Feng L, Yang Z, Zhou L, Duan X, Cheng S, Zhang W, Liu B, and Zhang K. Enhanced Therapeutic Efficacy Of A Novel Oncolytic Herpes Simplex Virus Type 2 encoding an antibody against programmed cell death 1. Mol Ther Oncolytics. 2019;15:201–13. doi:10.1016/j.omto.2019.10.003.
   PubMed Web of Science ®Google Scholar
• Khalique H, Baugh R, Dyer A, Scott EM, Frost S, Larkin S, Lei-Rossmann J, and Seymour LW. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. J Immunother Cancer. 2021;9(4). doi:10.1136/jitc-2020-001292.
   Web of Science ®Google Scholar
• Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, and Szalay AA. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A. 2009;106(31):12915–20. doi:10.1073/pnas.0900660106.
   PubMed Web of Science ®Google Scholar
• Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, Weibel S, Nolte I, Frentzen A, and Szalay AA. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. PLoS One. 2012;7(10):e47472. doi:10.1371/journal.pone.0047472.
   PubMed Web of Science ®Google Scholar
• Buckel L, Advani SJ, Frentzen A, Zhang Q, Yu YA, Chen NG, Ehrig K, Stritzker J, Mundt AJ, and Szalay AA. Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int J Cancer. 2013;133(12):2989–99.
   PubMed Web of Science ®Google Scholar
• Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, Adelfinger M, Gnamlin P, Kober C, Frentzen A, Gentschev I, et al., Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J Transl Med. 2013;11(1):106. doi:10.1186/1479-5876-11-106.
   PubMedGoogle Scholar
• Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014;22(1):102–11. doi:10.1038/mt.2013.240.
   PubMed Web of Science ®Google Scholar
• Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen CH, Lou E, Fujisawa S, Eveno C, Belin L, et al. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res Treat. 2014;148(3):489–99. doi:10.1007/s10549-014-3180-7.
   PubMed Web of Science ®Google Scholar
• Adelfinger M, Gentschev I, Grimm de Guibert J, Weibel S, Langbein-Laugwitz J, Härtl B, Murua Escobar H, Nolte I, Chen NG, Aguilar RJ, et al., Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy. PLoS One. 2014;9(8):e104337. doi:10.1371/journal.pone.0104337.
   PubMed Web of Science ®Google Scholar
• Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, and Szalay AA. Preclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF single-chain antibody for canine cancer therapy. Viruses. 2015;7(7):4075–92. doi:10.3390/v7072811.
   PubMed Web of Science ®Google Scholar
• Huang T, Wang H, Chen NG, Frentzen A, Minev B, Szalay AA. Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. Mol Ther Oncolytics. 2015;2:15003. doi:10.1038/mto.2015.3.
   PubMed Web of Science ®Google Scholar
• Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death −1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5(10):e1220467. doi:10.1080/2162402X.2016.1220467.
   PubMed Web of Science ®Google Scholar
• Yu F, Hong B, Song X-T. A T-cell engager-armed oncolytic vaccinia virus to target the tumor stroma. Cancer Transl Med. 2017;3(4):122–32.
   Google Scholar
• Zuo S, Wei M, He B, Chen A, Wang S, Kong L, Zhang Y, Meng G, Xu T, Wu J, et al. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). EBioMedicine. 2021;64:103240. doi:10.1016/j.ebiom.2021.103240.
   PubMed Web of Science ®Google Scholar
• Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S, Kanerva A, Pesonen S, Löskog A, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 2012;19(10):988–98. doi:10.1038/gt.2011.176.
   PubMed Web of Science ®Google Scholar
• Du T, Shi G, Li YM, Zhang JF, Tian HW, Wei YQ, Deng H, and Yu DC. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 2014;21(8):340–48. doi:10.1038/cgt.2014.34.
   PubMed Web of Science ®Google Scholar
• Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, and Hemminki A. Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer. Mol Cancer Ther. 2016;15(9):2259–69. doi:10.1158/1535-7163.MCT-15-0819.
   PubMed Web of Science ®Google Scholar
• Fernández-Ulibarri I, Hammer K, Arndt MA, Kaufmann JK, Dorer D, Engelhardt S, Kontermann RE, Hess J, Allgayer H, Krauss J, et al. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int J Cancer. 2015;136(9):2228–40. doi:10.1002/ijc.29258.
   PubMed Web of Science ®Google Scholar
• Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, and Alemany R. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 2017;77(8):2052–63. doi:10.1158/0008-5472.CAN-16-1708.
   PubMed Web of Science ®Google Scholar
• Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, Fisher KD, Champion BR, and Brown ACN. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS One. 2017;12(5):e0177810. doi:10.1371/journal.pone.0177810.
   PubMed Web of Science ®Google Scholar
• Wing A, Fajardo CA, Posey AD, Jr., Shaw C, Da T, Young RM, Alemany R, June CH, and Guedan S. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605–16. doi:10.1158/2326-6066.CIR-17-0314.
   PubMed Web of Science ®Google Scholar
• De Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer. 2019;7(1):19. doi:10.1186/s40425-019-0505-4.
   PubMedGoogle Scholar
• Barlabé P, Sostoa J, Fajardo CA, Alemany R, Moreno R. Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers. Cancer Gene Ther. 2020;27(5):383–88. doi:10.1038/s41417-019-0110-1.
   PubMed Web of Science ®Google Scholar
• Quirin C, Rohmer S, Fernandez-Ulibarri I, Behr M, Hesse A, Engelhardt S, Erbs P, Enk AH, and Nettelbeck DM. Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy. Hum Gene Ther. 2011;22(4):389–404. doi:10.1089/hum.2010.100.
   PubMed Web of Science ®Google Scholar
• Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, and Rosenberg SA. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210(6):1125–35. doi:10.1084/jem.20130110.
   PubMed Web of Science ®Google Scholar
• Hamilton JR, Vijayakumar G, Palese P. A recombinant antibody-expressing influenza virus delays tumor growth in a mouse model. Cell Rep. 2018;22(1):1–7. doi:10.1016/j.celrep.2017.12.025.
   PubMed Web of Science ®Google Scholar
• Rohmer S, Quirin C, Hesse A, Sandmann S, Bayer W, Herold-Mende C, Haviv YS, Wildner O, Enk AH, and Nettelbeck DM. Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. Virology. 2009;395(2):243–54. doi:10.1016/j.virol.2009.09.030.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst. 2006;98(20):1482–93. doi:10.1093/jnci/djj397.
   PubMedGoogle Scholar
• Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther. 2010;18(7):1275–83. doi:10.1038/mt.2010.79.
   PubMed Web of Science ®Google Scholar
• Pühler F, Willuda J, Puhlmann J, Mumberg D, Römer-Oberdörfer A, Beier R. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther. 2008;15(5):371–83. doi:10.1038/sj.gt.3303095.
   PubMed Web of Science ®Google Scholar
• Wei D, Li Q, Wang XL, Wang Y, Xu J, Feng F, Nan G, Wang B, Li C, Guo T, et al. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice. J Exp Clin Cancer Res. 2015;34(1):153. doi:10.1186/s13046-015-0271-1.
   PubMedGoogle Scholar
• Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW. Solid tumor immunotherapy with T cell engager-armed oncolytic viruses. Macromol Biosci. 2018;18(1). doi:10.1002/mabi.201700187.
   PubMed Web of Science ®Google Scholar
• Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol. 2021;14(1):63. doi:10.1186/s13045-021-01075-5.
   PubMed Web of Science ®Google Scholar
• Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, and Engeland CE. Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin Cancer Res. 2018;24(9):2128–37. doi:10.1158/1078-0432.CCR-17-2651.
   PubMed Web of Science ®Google Scholar
• Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 2007;67(12):5929–39. doi:10.1158/0008-5472.CAN-06-4296.
   PubMed Web of Science ®Google Scholar
• Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, and Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother. 2008;57(8):1263–70. doi:10.1007/s00262-008-0451-3.
   PubMed Web of Science ®Google Scholar
• Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res. 2013;19(19):5381–89. doi:10.1158/1078-0432.CCR-12-0781.
   PubMed Web of Science ®Google Scholar
• Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology. 2014;3(1):e27614. doi:10.4161/onci.27614.
   PubMed Web of Science ®Google Scholar
• Bartee MY, Dunlap KM, Bartee E. Tumor-localized secretion of soluble pd1 enhances oncolytic virotherapy. Cancer Res. 2017;77(11):2952–63. doi:10.1158/0008-5472.CAN-16-1638.
   PubMed Web of Science ®Google Scholar
• Woo Y, Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim SI, Warner SG, Von Hoff D, and Fong Y. Novel chimeric immuno-oncolytic virus CF33-hNIS-antiPDL1 for the treatment of pancreatic cancer. J Am Coll Surg. 2020;230(4):709–17. doi:10.1016/j.jamcollsurg.2019.12.027.
   PubMed Web of Science ®Google Scholar
• Vijayakumar G, McCroskery S, Palese P. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. J Virol. 2020;94(3). doi:10.1128/JVI.01677-19.
   PubMed Web of Science ®Google Scholar
• Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, et al., CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther. 2014;22(11):1949–59. doi:10.1038/mt.2014.160.
   PubMed Web of Science ®Google Scholar
• Wu C, Wu M, Liang M, Xiong S, Dong C. A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model. Cell Mol Immunol. 2019;16(9):780–82. doi:10.1038/s41423-019-0264-7.
   PubMed Web of Science ®Google Scholar
• Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine. 2019;49:96–105. doi:10.1016/j.ebiom.2019.10.032.
   PubMed Web of Science ®Google Scholar
• Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, and Chinot OL. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi:10.1016/j.ctrv.2020.102017.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim SI, et al. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther; 2021. doi: 10.1038/s41417-021-00350-4
   Google Scholar
• Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23–36. doi:10.1182/blood-2013-01-306647.
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res. 2015;21(24):5543–51. doi:10.1158/1078-0432.CCR-14-2009.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73. doi:10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies (Basel). 2020;9(4):1-34.
   Google Scholar
• Martineau P, Watier H, Pèlegrin A, Turtoi A. Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6(th) antibody industrial symposium, June 25- 26,2018, montpellier. France MAbs. 2019;11(5):812–25. doi:10.1080/19420862.2019.1612691.
   PubMed Web of Science ®Google Scholar
• Minter RR, Sandercock AM, Rust SJ. Phenotypic screening-the fast track to novel antibody discovery. Drug Discov Today Technol. 2017;23:83–90. doi:10.1016/j.ddtec.2017.03.004.
   PubMedGoogle Scholar
• Yang H, Kuo YH, Smith ZI, Spangler J. Targeting cancer metastasis with antibody therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021. e1698. Wiley.
   Google Scholar
• Marschall AL, Single FN, Schlarmann K, Bosio A, Strebe N, van den Heuvel J, et al.Marschall AL, Single FN, Schlarmann K, Bosio A, Strebe N, van den Heuvel J, Frenzel A, and Dübel S Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies. MAbs. 2014;6(6):1394–401. doi:10.4161/mabs.34377.
   PubMed Web of Science ®Google Scholar
• Zhang C, Ötjengerdes RM, Roewe J, Mejias R, Marschall ALJ. Applying antibodies inside cells: principles and recent advances in neurobiology, virology and oncology. BioDrugs. 2020;34:435–62.
   PubMed Web of Science ®Google Scholar
• Büssow K, Themann P, Luu S, Pentrowski P, Harting C, Majewski M, Vollmer V, Köster M, Grashoff M, Zawatzky R, et al., ER intrabody-mediated inhibition of interferon α secretion by mouse macrophages and dendritic cells. PLoS One. 2019;14(4):e0215062. doi:10.1371/journal.pone.0215062.
   PubMed Web of Science ®Google Scholar
• Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109:74–103.
   PubMed Web of Science ®Google Scholar
• Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. 2017;122:2–19. doi:10.1016/j.addr.2016.11.004.
   PubMed Web of Science ®Google Scholar
• Runcie K, Budman DR, John V, Seetharamu N. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Mol Med. 2018;24(1):50. doi:10.1186/s10020-018-0051-4.
   PubMedGoogle Scholar
• Murer P, Neri D. Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol. 2019;52:42–53. doi:10.1016/j.nbt.2019.04.002.
   PubMed Web of Science ®Google Scholar